Stockpolly
Search
Delisting risk
LIMN · NASDAQ · Biotechnology

Liminatus Pharma Class A (LIMN)

Develops oncology antibodies and autologous CAR-T candidates through a license- and partner-dependent model.

$3.88
Pre-market+0.04 (+1.04%)
At close$3.84(+5.35%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue000000000000
Gross profit000000000000
112111011111
Research & development012100000001
100000011111
General & administrative000000011111
Other expenses000000000000
Operating income−1−1−2−1−1−10−1−1−1−1−1
00000001−1−700
Interest income000000000000
Interest expense000000000000
Other non-operating income0000000−11700
Income before tax00−2−1−1−100−2−8−1−1
Income tax expense000000000000
Net income from continuing operations00−2−1−1−100−2−8−1−1
Net income00−2−1−1−100−2−8−1−1
EPS, basic−$0.04−$3.33−$11.50−$3.72−$4.48−$6.00−$127.50$0.25−$3.38−$15.00−$2.37−$2.96
EPS, diluted−$0.04−$3.33−$11.50−$3.72−$4.48−$6.00−$127.50$0.25−$3.38−$15.00−$2.37−$2.96
Weighted average shares, basic800000101000
Weighted average shares, diluted800000101000
EBITDA00−2−1−1−100−2−8−1−1
Depreciation & amortization000000000000
EBIT00−2−1−1−100−2−8−1−1